ANLIVA DBS

Deep Brain Stimulation (DBS) is a well-established therapy for late-stage Parkinson’s disease. Calibrating DBS settings can be both complex and time-consuming. ANLIVA® Deep Brain Stimulation aims for automatic signal programming. Our solution creates a digital twin of the patients brain to predict treatment response and suggest optimal settings.

• In DBS treatment, electrodes implanted into the brain stimulate motor control using well-defined electrical fields. Settings are tailored for each patient.
• Several parameters, including stimulation amplitude, pulse width, frequency, and the contact configuration, need to be adjusted in a perfect combination for best symptom relief without inducing side-effects. Patient revisits to fine-tune these settings are common.
• ANLIVA® DBS aims to predict optimal DBS settings by analyzing electrode placement and neural conductivity in a digital twin of the patients brain.
• We develop ANLIVA® DBS as a standalone SaMD for use with major DBS systems, including those from Medtronic, Abbott, and Boston Scientific, making it a vendor-agnostic solution.

Clinical trials in collaboration with Dartmouth-Hitchcock Clinic (USA) are underway, with FDA 510(k) clearance targeted for the end of 2026. DBS vendor-agnostic solution. Patent pending.

Despite being an established therapy for Parkinson’s Disease, deep brain stimulation (DBS) still relies on a manual trial-and-error procedure to achieve clinical efficacy for the patient. ANLIVA® DBS is a medical device that employs sophisticated mathematical modeling aiming to significantly improve treatment outcomes and enhance the cost-effectiveness of DBS.

In DBS, electrical pulses are delivered to neural targets deep inside the brain through implanted electrodes to alleviate motor symptoms. To achieve a successful outcome, the stimulation must be adjusted effectively to maximize the symptom relief while avoiding DBS-induced side effects – a process that is currently done in a time-consuming calibration procedure, both burdening the patient and healthcare resources.

Intensity-based segmentation of an MR image to identify grey matter, white matter and cerebrospinal fluid is used to obtain patient-specific conductivity models for DBS simulation

The animation below demonstrates the optimized activation field in Deep Brain Stimulation targeting the subthalamic nucleus (STN) motor region in Parkinson’s Disease (PD).  By optimizing the electric field to precisely target the STN motor, the motor symptoms of PD are addressed while minimizing potential side-effects.

ANLIVA® DBS is intended to automate the process of tailoring DBS by mathematically predicting clinically efficacious DBS settings by employing a digital twin strategy based on patient-specific neural imaging data, where the stimulation is computationally optimized with respect to neural targets.